Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 19 for:    sasa

A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05025072
Recruitment Status : Completed
First Posted : August 27, 2021
Last Update Posted : October 7, 2021
Sponsor:
Collaborators:
Simbec Orion
Oncodesign SA
PHINC DEVELOPMENT
Information provided by (Responsible Party):
ADDMEDICA SASA

Tracking Information
First Submitted Date  ICMJE August 5, 2021
First Posted Date  ICMJE August 27, 2021
Last Update Posted Date October 7, 2021
Actual Study Start Date  ICMJE August 22, 2021
Actual Primary Completion Date September 29, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 23, 2021)
  • Cmax [ Time Frame: 24 hours ]
    The observed maximum concentration (Cmax) in plasma
  • AUC0-t [ Time Frame: 24 hours ]
    The area under the plasma concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration (t)
  • AUC0-infinity [ Time Frame: 24 hours ]
    The AUC from time 0 to infinity
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 23, 2021)
  • tmax [ Time Frame: 24 hours ]
    The time at which Cmax is apparent
  • t1/2 [ Time Frame: 24 hours ]
    The terminal elimination half-life
  • ke [ Time Frame: 24 hours ]
    The terminal elimination rate-constant
  • AUC%extra [ Time Frame: 24 hours ]
    % of AUC0-infinity extrapolated
  • Adverse events [ Time Frame: 24 hours ]
    Incidence of Adverse Events
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers
Official Title  ICMJE A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers
Brief Summary

This study is a Phase I, open-label, single-centre, randomised, two-period, single-dose crossover study to compare and assess the bioequivalence, safety, tolerability and pharmacokinetics of hydroxycarbamide dispersible tablets (20 x 50 mg) (test IMP) and Siklos® film-coated tablet (1000 mg) (reference IMP) following single-dose administration. Thirty (30) healthy male and female participants, between 18 and 50 years of age are planned to participate in the study.

Study participants will be randomised to one of the 2 possible combination sequences. After each treatment administration, blood samples will be collected at specific time points to assess the Pharmacokinetics (PK) parameters.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Condition  ICMJE Healthy Volunteers
Intervention  ICMJE
  • Drug: Hydroxycarbamide dispersible tablets
    Hydroxycarbamide dispersible tablets (20 x 50 mg)
  • Drug: Hydroxycarbamide film-coated tablet
    Hydroxycarbamide film-coated tablet (1000 mg)
Study Arms  ICMJE
  • Experimental: Test IMP
    Hydroxycarbamide dispersible tablets (20 x 50 mg)
    Interventions:
    • Drug: Hydroxycarbamide dispersible tablets
    • Drug: Hydroxycarbamide film-coated tablet
  • Active Comparator: Reference IMP
    Hydroxycarbamide film-coated tablet (1000 mg)
    Interventions:
    • Drug: Hydroxycarbamide dispersible tablets
    • Drug: Hydroxycarbamide film-coated tablet
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 6, 2021)
28
Original Estimated Enrollment  ICMJE
 (submitted: August 23, 2021)
30
Actual Study Completion Date  ICMJE September 29, 2021
Actual Primary Completion Date September 29, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Healthy male and female participants, between 18 and 50 years of age, inclusive.
  2. Female participant of childbearing potential willing to use a highly effective method of contraception, if applicable from the first dose until 3 months after the last dose of IMP.
  3. Female participant of non-childbearing potential. For the purposes of this study, this is defined as the participant being amenorrhoeic for at least 12 consecutive months or at least 4 months post-surgical sterilisation.
  4. Female participant with a negative pregnancy test at Screening.
  5. Male participant (and partner of child bearing potential) willing to use a highly method of contraception, if applicable from first dose until 3 months after last dose of IMP.
  6. Participant with a BMI of 18-29.9 kg/m2.
  7. No clinically significant history of previous allergy / sensitivity to hydroxycarbamide or any of the excipients contained within the IMP(s).
  8. No clinically significant abnormal test results for serum biochemistry, haematology and/or urine analyses within 28 days before the first dose administration of the IMP.
  9. Participant with a negative urinary DOA screen (including alcohol) test results, determined within 28 days before the first dose administration of the IMP.
  10. Participant with negative human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCV Ab) test results at Screening.
  11. No clinically significant abnormalities in 12-lead ECG determined within 28 days before the first dose of IMP.
  12. No clinically significant abnormalities in vital signs determined within 28 days before the first dose of IMP.
  13. Participant must be available to complete the study.
  14. Participant must satisfy an Investigator about his/her fitness to participate in the study.
  15. Participant must provide written informed consent to participate in the study.

Exclusion Criteria:

  1. A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.
  2. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 28 days or 5 half-lives prior to the first dose of IMP.
  3. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction.
  4. A clinically significant history of drug or alcohol abuse within the past two years.
  5. Inability to communicate well with the Investigators.
  6. Participation in a New Chemical Entity clinical study within the previous 3 months or five half-lives whichever is the longest, or a marketed drug clinical study within the 30 days or five half-lives whichever is the longest, before the first dose of IMP.
  7. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.
  8. Users of nicotine products i.e., current smokers or ex-smokers who have smoked within 6 months prior to Screening or users of cigarette replacements
  9. Female participants who are pregnant, breastfeeding or lactating.
  10. Participants who have received any live or attenuated vaccine within 28 days of the first dose of IMP, or who are planning to receive a vaccine up to 28 days after receiving the last dose of IMP in Treatment Period 2.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 50 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05025072
Other Study ID Numbers  ICMJE SIK-FR-21-1
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party ADDMEDICA SASA
Study Sponsor  ICMJE ADDMEDICA SASA
Collaborators  ICMJE
  • Simbec Orion
  • Oncodesign SA
  • PHINC DEVELOPMENT
Investigators  ICMJE
Principal Investigator: Annelize Koch, MD Simbec Orion
PRS Account ADDMEDICA SASA
Verification Date October 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP